https://m2.mtmt.hu/ eng 2026-09-20 23:13 JournalArticle 35579438 VALIDATED true These authors contributed equally: Laura Vízkeleti and Orsolya Papp. 0 false 2026-06-02T11:10:59.727+0000 2024-11-26T08:27:19.756+0000 2024-11-19T10:24:31.613+0000 true 10069606 Pintér Ibolya Katalin /api/admin/10069606 Admin Ibolya Katalin Pintér (SE_AOK_TranszlációsMedInt_Admin5_PI, admin) true 2026-07-11T16:29:00.387+0000 2026-07-11T16:29:00.387+0000 2024-11-19T12:24:40.866+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Ágnes Szalóky-Siki (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Article (Journal Article) 101 true 10000059 true 1 /api/category/1 Category Scientific true 1 Vízkeleti, Laura true true /api/journal/10019966 REVIEWED SCIENTIFIC REPORTS 2045-2322 true false 10019966 false 10019966 true 2045-2322 Journal FOREIGN 14 1 26540 26540 16 2024 Funding 2046681 /api/funding/2046681 (K135540) Funder: HSRF false true Funding 2046682 /api/funding/2046682 (TKP21-EGA25) false true Funding 2046683 /api/funding/2046683 (NN 114460) Funder: HSRF false true true true 2024 true true true false true false GOLD 2026-06-02 false http://www.nature.com/srep/index.html 4 0 4 2 2 4 4 4 2 4 4 2 2 2 2 0 4 2 4 2 0 9 9 Folyóiratcikk Journal Article 24 4 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 3 1 3 1 2026 0 1 1 1 1 Q1 A nemzetközi false 10034960,10000584 false false false 2024-11-18T12:24:40.442+0000 Bioinformatika Tanszék (SE / AOK / I); Bőr-, Nemikórtani és Bőronkológiai Klinika (SE / AOK / K); Doktori Iskola (SE); Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 7 50 4 9 0 true Language 10002 /api/language/10002 English Angol English true 2 true PersonAuthorship 121679542 /api/authorship/121679542 Vízkeleti, Laura [Vízkeleti, Laura (molekuláris bioló...), author] Bioinformatika Tanszék (SU / FM / I); Patológiai, Igazságügyi és Biztosítási Orvostan... (SU / FM / I) 1 0.111 true false false Author 10034960 /api/author/10034960 Laura Vízkeleti (molekuláris biológia, daganat (epi)genomika) Vízkeleti Laura true 10034960 true Vízkeleti Laura true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 121679543 /api/authorship/121679543 Papp, Orsolya* [Papp, Orsolya (molekuláris onkol...), author] Patológiai, Igazságügyi és Biztosítási Orvostan... (SU / FM / I) 2 0.111 true false false Author 10055100 /api/author/10055100 Orsolya Papp (molekuláris onkológia) Papp Orsolya true 10055100 true Papp Orsolya true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 121679544 /api/authorship/121679544 Doma, Viktória [Doma, Viktória (dermatológia, onk...), author] Department of Dermatology, Dermatooncology and ... (SU / FM / C); Patológiai, Igazságügyi és Biztosítási Orvostan... (SU / FM / I) 3 0.111 false false false Author 10048941 /api/author/10048941 Viktória Doma (dermatológia, onkológia) Doma Viktória true 10048941 true Doma Viktória true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 121679545 /api/authorship/121679545 Gil, Jeovanis 4 0.11111111 false false false Gil Jeovanis true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 121679546 /api/authorship/121679546 Markó-Varga, György 5 0.11111111 false false false Markó-Varga György true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 121679547 /api/authorship/121679547 Kovács, Szonja A. [Kovács, Szonja Anna (Molekuláris biológia), author] Bioinformatika Tanszék (SU / FM / I); School of PhD Studies (SU) 6 0.111 false false false Author 10081093 /api/author/10081093 Szonja Anna Kovács (Molekuláris biológia) Kovács Szonja Anna true true Kovács Szonja A. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 121679548 /api/authorship/121679548 Győrffy, Balázs [Győrffy, Balázs (Onkológia), author] Bioinformatika Tanszék (SU / FM / I) 7 0.111 false false false Author 10000109 /api/author/10000109 Balázs Győrffy (Onkológia) Győrffy Balázs true 10000109 true Győrffy Balázs true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 121679549 /api/authorship/121679549 Kárpáti, Sarolta [Kárpáti, Sarolta (Bõrgyógyászat, ge...), author] Department of Dermatology, Dermatooncology and ... (SU / FM / C) 8 0.111 false false false Author 10002737 /api/author/10002737 Sarolta Kárpáti (Bõrgyógyászat, genetika) Kárpáti Sarolta true 10002737 true Kárpáti Sarolta true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 121679550 /api/authorship/121679550 Tímár, József ✉ [Tímár, József (Rákkutatás, dagan...), author] Patológiai, Igazságügyi és Biztosítási Orvostan... (SU / FM / I) 9 0.111 false true true Author 10000584 /api/author/10000584 József Tímár (Rákkutatás, daganatpathológia) Tímár József true 10000584 true Tímár József true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PublicationIdentifier 27943617 /api/publicationidentifier/27943617 DOI: 10.1038/s41598-024-77285-x PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1038/s41598-024-77285-x https://doi.org/10.1038/s41598-024-77285-x false true PublicationIdentifier 28010280 /api/publicationidentifier/28010280 WoS: 001349432200015 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001349432200015 https://www.webofscience.com/wos/woscc/full-record/001349432200015 true true PublicationIdentifier 27945284 /api/publicationidentifier/27945284 Scopus: 85208470617 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85208470617 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85208470617 false true PublicationIdentifier 27945283 /api/publicationidentifier/27945283 PubMed: 39489756 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39489756 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39489756&dopt=Abstract false true MtaRating 519359 /api/mtarating/519359 IX. Committee on Sociology:A nemzetközi SCIENTIFIC REPORTS 2045-2322 RatingType 10007 /api/ratingtype/10007 IX. Committee on Sociology SZTB Institute 14102 /api/institute/14102 Committee on Sociology HASSELIX SZTB [1901-] 0 false true false Szociológiai Tudományos Bizottság Committee on Sociology true 14102 true true true A nemzetközi true 19359 true MtaRating 11551161 /api/mtarating/11551161 IX. Committee on Regional Studies:B nemzetközi SCIENTIFIC REPORTS 2045-2322 RatingType 10010 /api/ratingtype/10010 IX. Committee on Regional Studies RegTB Institute 14100 /api/institute/14100 Committee on Regional Studies HASSELIX RTB [1901-] 0 false true false Regionális Tudományok Bizottsága Committee on Regional Studies true 14100 true true true B nemzetközi false true SjrRating 11736109 /api/sjrrating/11736109 sjr:Q1 (2024) Scopus - Multidisciplinary SCIENTIFIC REPORTS 2045-2322 23 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1000 /api/classificationexternal/1000 Scopus - Multidisciplinary true 1000 true Q1 DIRECT true true Reference 59953635 /api/reference/59953635 1. Lee, A. J. & Ashkar, A. A. The dual nature of type I and type II interferons. Front. Immunol. 9, 2061. https://doi.org/10.3389/fimmu.2018.02061 (2018)., DOI: 10.3389/fimmu.2018.02061 1 10.3389/fimmu.2018.02061 false true Reference 59953636 /api/reference/59953636 2. Rusinova, I. et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040-1046. https://doi.org/10.1093/nar/gks1215 (2013)., DOI: 10.1093/nar/gks1215 2 10.1093/nar/gks1215 false true Reference 59953637 /api/reference/59953637 3. Lu, M. et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp. Hematol. 38, 472–480. https://doi.org/10.1016/j.exphem.2010.03.005 (2010)., DOI: 10.1016/j.exphem.2010.03.005 3 10.1016/j.exphem.2010.03.005 false true Reference 59953638 /api/reference/59953638 4. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414. https://doi.org/10.1038/nri3845 (2015)., DOI: 10.1038/nri3845 4 10.1038/nri3845 false true Reference 59953639 /api/reference/59953639 5. Kang, K., Xie, F., Mao, J., Bai, Y. & Wang, X. Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma. Front. Oncol. 10, 573141. https://doi.org/10.3389/fonc.2020.573141 (2020)., DOI: 10.3389/fonc.2020.573141 5 10.3389/fonc.2020.573141 false true Reference 59953640 /api/reference/59953640 6. Di Trolio, R., Simeone, E., Di Lorenzo, G., Buonerba, C. & Ascierto, P. A. The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev. 26, 203–212. https://doi.org/10.1016/j.cytogfr.2014.11.008 (2015)., DOI: 10.1016/j.cytogfr.2014.11.008 6 10.1016/j.cytogfr.2014.11.008 false true Reference 59953641 /api/reference/59953641 7. Rozeman, E. A. et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat. Med. 27, 256–263. https://doi.org/10.1038/s41591-020-01211-7 (2021)., DOI: 10.1038/s41591-020-01211-7 7 10.1038/s41591-020-01211-7 false true Reference 59953642 /api/reference/59953642 8. Certa, U., Seiler, M., Padovan, E. & Spagnoli, G. C. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells. Br. J. Cancer. 85, 107–114. https://doi.org/10.1054/bjoc.2001.1865 (2001)., DOI: 10.1054/bjoc.2001.1865 8 10.1054/bjoc.2001.1865 false true Reference 59953643 /api/reference/59953643 9. Krepler, C. et al. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J. Investig. Dermatol. 123, 664–669. https://doi.org/10.1111/j.0022-202X.2004.23433.x (2004)., DOI: 10.1111/j.0022-202X.2004.23433.x 9 10.1111/j.0022-202X.2004.23433.x false true Reference 59953644 /api/reference/59953644 10. Katlinskaya, Y. V. et al. Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep. 15, 171–180. https://doi.org/10.1016/j.celrep.2016.03.006 (2016)., DOI: 10.1016/j.celrep.2016.03.006 10 10.1016/j.celrep.2016.03.006 false true Reference 59953645 /api/reference/59953645 11. Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 167, 397-404.e399. https://doi.org/10.1016/j.cell.2016.08.069 (2016)., DOI: 10.1016/j.cell.2016.08.069 11 10.1016/j.cell.2016.08.069 false true Reference 59953646 /api/reference/59953646 12. Rodriguez, T. et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer. 7, 34. https://doi.org/10.1186/1471-2407-7-34 (2007)., DOI: 10.1186/1471-2407-7-34 12 10.1186/1471-2407-7-34 false true Reference 59953647 /api/reference/59953647 13. Alavi, S. et al. Interferon signaling is frequently downregulated in melanoma. Front Immunol. 9, 1414. https://doi.org/10.3389/fimmu.2018.01414 (2018)., DOI: 10.3389/fimmu.2018.01414 13 10.3389/fimmu.2018.01414 false true Reference 59953648 /api/reference/59953648 14. Buzzai, A. C. et al. Diverse anti-tumor immune potential driven by individual IFNalpha subtypes. Front. Immunol. 11, 542. https://doi.org/10.3389/fimmu.2020.00542 (2020)., DOI: 10.3389/fimmu.2020.00542 14 10.3389/fimmu.2020.00542 false true Reference 59953649 /api/reference/59953649 15. Heise, R. et al. Interferon alpha signalling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma. PLoS ONE. 11, e0146325. https://doi.org/10.1371/journal.pone.0146325 (2016)., DOI: 10.1371/journal.pone.0146325 15 10.1371/journal.pone.0146325 false true Reference 59953650 /api/reference/59953650 16. Ladanyi, A. et al. Identification of a tumor cell associated type I IFN resistance gene expression signature of human melanoma, the components of which have a predictive potential for immunotherapy. Int. J. Mol. Sci. https://doi.org/10.3390/ijms23052704 (2022)., DOI: 10.3390/ijms23052704 16 10.3390/ijms23052704 false true Reference 59953651 /api/reference/59953651 17. Betancourt, L. H. et al. The human melanoma proteome atlas-defining the molecular pathology. Clin Transl. Med. 11, e473. https://doi.org/10.1002/ctm2.473 (2021)., DOI: 10.1002/ctm2.473 17 10.1002/ctm2.473 false true Reference 59953652 /api/reference/59953652 18. Betancourt, L. H. et al. The human melanoma proteome atlas-complementing the melanoma transcriptome. Clin. Transl. Med. 11, e451. https://doi.org/10.1002/ctm2.451 (2021)., DOI: 10.1002/ctm2.451 18 10.1002/ctm2.451 false true Reference 59953653 /api/reference/59953653 19. Gil, J. et al. An observational study on the molecular profiling of primary melanomas reveals a progression dependence on mitochondrial activation. Cancers. https://doi.org/10.3390/cancers13236066 (2021)., DOI: 10.3390/cancers13236066 19 10.3390/cancers13236066 false true Reference 59953654 /api/reference/59953654 20. Doma, V., Karpati, S., Raso, E., Barbai, T. & Timar, J. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. BMC Cancer. 19, 786. https://doi.org/10.1186/s12885-019-5990-9 (2019)., DOI: 10.1186/s12885-019-5990-9 20 10.1186/s12885-019-5990-9 false true Reference 59953655 /api/reference/59953655 21. Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res. 52, D672–D678. https://doi.org/10.1093/nar/gkad1025 (2024)., DOI: 10.1093/nar/gkad1025 21 10.1093/nar/gkad1025 false true Reference 59953656 /api/reference/59953656 22. Papp, O. et al. Organ specific copy number variations in visceral metastases of human melanoma. Cancers. https://doi.org/10.3390/cancers13235984 (2021)., DOI: 10.3390/cancers13235984 22 10.3390/cancers13235984 false true Reference 59953657 /api/reference/59953657 23. Timar, J., Honn, K. V., Hendrix, M. J. C., Marko-Varga, G. & Jalkanen, S. Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry. Cancer Metastasis Rev. 42, 323–334. https://doi.org/10.1007/s10555-023-10087-1 (2023)., DOI: 10.1007/s10555-023-10087-1 23 10.1007/s10555-023-10087-1 false true Reference 59953658 /api/reference/59953658 24. Marchi, L. F., Sesti-Costa, R., Ignacchiti, M. D., Chedraoui-Silva, S. & Mantovani, B. In vitro activation of mouse neutrophils by recombinant human interferon-gamma: increased phagocytosis and release of reactive oxygen species and pro-inflammatory cytokines. Int. Immunopharmacol. 18, 228–235. https://doi.org/10.1016/j.intimp.2013.12.010 (2014)., DOI: 10.1016/j.intimp.2013.12.010 24 10.1016/j.intimp.2013.12.010 false true Reference 59953659 /api/reference/59953659 25. Ermis Akyuz, E. & Bell, S. M. The diverse role of CUB and Sushi Multiple Domains 1 (CSMD1) in human diseases. Genes. https://doi.org/10.3390/genes13122332 (2022)., DOI: 10.3390/genes13122332 25 10.3390/genes13122332 false true Reference 59953660 /api/reference/59953660 26. Li, D. et al. Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4. Nat. Commun. 9, 2829. https://doi.org/10.1038/s41467-018-05286-2 (2018)., DOI: 10.1038/s41467-018-05286-2 26 10.1038/s41467-018-05286-2 false true Reference 59953661 /api/reference/59953661 27. Vandamme, N. et al. The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype. Cancer Res. 80, 2983–2995. https://doi.org/10.1158/0008-5472.CAN-19-2373 (2020)., DOI: 10.1158/0008-5472.CAN-19-2373 27 10.1158/0008-5472.CAN-19-2373 false true Reference 59953662 /api/reference/59953662 28. Barrow, J. et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol. 13, 212–222. https://doi.org/10.1093/neuonc/noq158 (2011)., DOI: 10.1093/neuonc/noq158 28 10.1093/neuonc/noq158 false true Reference 59953663 /api/reference/59953663 29. Mologni, L. et al. Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells. Neoplasia. 20, 467–477. https://doi.org/10.1016/j.neo.2018.02.009 (2018)., DOI: 10.1016/j.neo.2018.02.009 29 10.1016/j.neo.2018.02.009 false true Reference 59953664 /api/reference/59953664 30. Emmons, M. F. et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Res. 79, 2947–2961. https://doi.org/10.1158/0008-5472.CAN-19-0040 (2019)., DOI: 10.1158/0008-5472.CAN-19-0040 30 10.1158/0008-5472.CAN-19-0040 false true Reference 59953665 /api/reference/59953665 31. Klaestad, E. et al. ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes. Breast Cancer Res. Treat. 186, 65–77. https://doi.org/10.1007/s10549-020-06035-0 (2021)., DOI: 10.1007/s10549-020-06035-0 31 10.1007/s10549-020-06035-0 false true Reference 59953666 /api/reference/59953666 32. Lucarini, V. et al. Combining type I interferons and 5-Aza-2’-deoxycitidine to improve anti-tumor response against melanoma. J. Investig. Dermatol. 137, 159–169. https://doi.org/10.1016/j.jid.2016.08.024 (2017)., DOI: 10.1016/j.jid.2016.08.024 32 10.1016/j.jid.2016.08.024 false true Reference 59953667 /api/reference/59953667 33. White, J. R. et al. AP-2alpha-mediated activation of E2F and EZH2 drives melanoma metastasis. Cancer Res. 81, 4455–4470. https://doi.org/10.1158/0008-5472.CAN-21-0772 (2021)., DOI: 10.1158/0008-5472.CAN-21-0772 33 10.1158/0008-5472.CAN-21-0772 false true Reference 59953668 /api/reference/59953668 34. Zhang, S., Wan, H. & Zhang, X. LncRNA LHFPL3-AS1 contributes to tumorigenesis of melanoma stem cells via the miR-181a-5p/BCL2 pathway. Cell Death Dis. 11, 950. https://doi.org/10.1038/s41419-020-03141-1 (2020)., DOI: 10.1038/s41419-020-03141-1 34 10.1038/s41419-020-03141-1 false true Reference 59953669 /api/reference/59953669 35. Tigyi, G. et al. Anti-cancer strategies targeting the autotaxin-lysophosphatidic acid receptor axis: is there a path forward?. Cancer Metastasis Rev. 40, 3–5. https://doi.org/10.1007/s10555-021-09955-5 (2021)., DOI: 10.1007/s10555-021-09955-5 35 10.1007/s10555-021-09955-5 false true Reference 59953670 /api/reference/59953670 36. Huang, C., Sheng, Y., Jia, J. & Chen, L. Identification of melanoma biomarkers based on network modules by integrating the human signaling network with microarrays. J. Cancer Res. Ther. 10(Suppl), C114-124. https://doi.org/10.4103/0973-1482.145816 (2014)., DOI: 10.4103/0973-1482.145816 36 10.4103/0973-1482.145816 false true Reference 59953671 /api/reference/59953671 37. Xu, X. et al. Gain of Chromosome 1q perturbs a competitive endogenous RNA network to promote melanoma metastasis. Cancer Res. 82, 3016–3031. https://doi.org/10.1158/0008-5472.CAN-22-0283 (2022)., DOI: 10.1158/0008-5472.CAN-22-0283 37 10.1158/0008-5472.CAN-22-0283 false true Reference 59953672 /api/reference/59953672 38. Romano, S. et al. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. Pigment Cell Melanoma Res. 28, 442–452. https://doi.org/10.1111/pcmr.12378 (2015)., DOI: 10.1111/pcmr.12378 38 10.1111/pcmr.12378 false true Reference 59953673 /api/reference/59953673 39. Ke, J. et al. Melanoma migration is promoted by prion protein via Akt-hsp27 signaling axis. Biochem. Biophys. Res. Commun. 523, 375–381. https://doi.org/10.1016/j.bbrc.2019.12.042 (2020)., DOI: 10.1016/j.bbrc.2019.12.042 39 10.1016/j.bbrc.2019.12.042 false true Reference 59953674 /api/reference/59953674 40. Xu, J. et al. LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression. Melanoma Res. 32, 218–230. https://doi.org/10.1097/CMR.0000000000000803 (2022)., DOI: 10.1097/CMR.0000000000000803 40 10.1097/CMR.0000000000000803 false true Reference 59953675 /api/reference/59953675 41. Takeda, K. et al. IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat. Commun. 8, 14607. https://doi.org/10.1038/ncomms14607 (2017)., DOI: 10.1038/ncomms14607 41 10.1038/ncomms14607 false true Reference 59953676 /api/reference/59953676 42. Hoekstra, M. E. et al. Long-distance modulation of bystander tumor cells by CD8(+) T cell-secreted IFNgamma. Nat. Cancer. 1, 291–301. https://doi.org/10.1038/s43018-020-0036-4 (2020)., DOI: 10.1038/s43018-020-0036-4 42 10.1038/s43018-020-0036-4 false true Reference 59953677 /api/reference/59953677 43. Thibaut, R. et al. Bystander IFN-gamma activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat. Cancer. 1, 302–314. https://doi.org/10.1038/s43018-020-0038-2 (2020)., DOI: 10.1038/s43018-020-0038-2 43 10.1038/s43018-020-0038-2 false true Reference 59953678 /api/reference/59953678 44. Schaefer, E. J. et al. BCOR and BCORL1 mutations drive epigenetic reprogramming and oncogenic signaling by unlinking PRC1.1 from target genes. Blood Cancer Discov. 3, 116–135. https://doi.org/10.1158/2643-3230.BCD-21-0115 (2022)., DOI: 10.1158/2643-3230.BCD-21-0115 44 10.1158/2643-3230.BCD-21-0115 false true Reference 59953679 /api/reference/59953679 45. Meng, J. et al. Rb selectively inhibits innate IFN-beta production by enhancing deacetylation of IFN-beta promoter through HDAC1 and HDAC8. J. Autoimmun. 73, 42–53. https://doi.org/10.1016/j.jaut.2016.05.012 (2016)., DOI: 10.1016/j.jaut.2016.05.012 45 10.1016/j.jaut.2016.05.012 false true Reference 59953680 /api/reference/59953680 46. Bald, T. et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 4, 674–687. https://doi.org/10.1158/2159-8290.CD-13-0458 (2014)., DOI: 10.1158/2159-8290.CD-13-0458 46 10.1158/2159-8290.CD-13-0458 false true Reference 59953681 /api/reference/59953681 47. Fragale, A. et al. Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects. Int. J. Cancer. 153, 1080–1095. https://doi.org/10.1002/ijc.34602 (2023)., DOI: 10.1002/ijc.34602 47 10.1002/ijc.34602 false true Reference 59953682 /api/reference/59953682 48. Razaghi, A., Durand-Dubief, M., Brusselaers, N. & Bjornstedt, M. Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy. Front. Immunol. 14, 1249330. https://doi.org/10.3389/fimmu.2023.1249330 (2023)., DOI: 10.3389/fimmu.2023.1249330 48 10.3389/fimmu.2023.1249330 false true Reference 59953683 /api/reference/59953683 49. Marzese, D. M., Huynh, J. L., Kawas, N. P. & Hoon, D. S. Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Genom. Data. 2, 150–152. https://doi.org/10.1016/j.gdata.2014.06.007 (2014)., DOI: 10.1016/j.gdata.2014.06.007 49 10.1016/j.gdata.2014.06.007 false true Reference 59953684 /api/reference/59953684 50. Rabbie, R. et al. The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. Br. J. Cancer. 124, 156–160. https://doi.org/10.1038/s41416-020-01090-2 (2021)., DOI: 10.1038/s41416-020-01090-2 50 10.1038/s41416-020-01090-2 false true Reference 59953685 /api/reference/59953685 51. Manca, A. et al. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. J. Transl. Med. 17, 289. https://doi.org/10.1186/s12967-019-2039-4 (2019)., DOI: 10.1186/s12967-019-2039-4 51 10.1186/s12967-019-2039-4 false true Reference 59953686 /api/reference/59953686 52. Forschner, A. et al. Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition. Int. J. Cancer. https://doi.org/10.1002/ijc.35103 (2024)., DOI: 10.1002/ijc.35103 52 10.1002/ijc.35103 false true /api/publication/35579438 Vízkeleti Laura et al. Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma. (2024) SCIENTIFIC REPORTS 2045-2322 14 1<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10034960"><a href="/gui2/?type=authors&mode=browse&sel=10034960" target="_blank">Vízkeleti Laura (<span class="authorship-author-name">Vízkeleti Laura</span> <span class="authorAux-mtmt"> molekuláris biológia, daganat (epi)genomika</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Bioinformatika Tanszék; <span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10055100"><a href="/gui2/?type=authors&mode=browse&sel=10055100" target="_blank">Papp Orsolya^* (<span class="authorship-author-name">Papp Orsolya</span> <span class="authorAux-mtmt"> molekuláris onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10048941"><a href="/gui2/?type=authors&mode=browse&sel=10048941" target="_blank">Doma Viktória (<span class="authorship-author-name">Doma Viktória</span> <span class="authorAux-mtmt"> dermatológia, onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Dermatology, Dermatooncology and Venerology; <span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Gil Jeovanis </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Markó-Varga György </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10081093"><a href="/gui2/?type=authors&mode=browse&sel=10081093" target="_blank">Kovács Szonja A. (<span class="authorship-author-name">Kovács Szonja Anna</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Bioinformatika Tanszék; <span title="Semmelweis University">SU</span>/School of PhD Studies</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000109"><a href="/gui2/?type=authors&mode=browse&sel=10000109" target="_blank">Győrffy Balázs (<span class="authorship-author-name">Győrffy Balázs</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Bioinformatika Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002737"><a href="/gui2/?type=authors&mode=browse&sel=10002737" target="_blank">Kárpáti Sarolta (<span class="authorship-author-name">Kárpáti Sarolta</span> <span class="authorAux-mtmt"> Bõrgyógyászat, genetika</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Dermatology, Dermatooncology and Venerology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000584"><a href="/gui2/?type=authors&mode=browse&sel=10000584" target="_blank">Tímár József ✉ (<span class="authorship-author-name">Tímár József</span> <span class="authorAux-mtmt"> Rákkutatás, daganatpathológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35579438" target="_blank">Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma</a></div> <div> <span class="journal-title">SCIENTIFIC REPORTS</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2045-2322">2045-2322</a>)</span>: <span class="journal-volume">14</span> <span class="journal-issue">1</span> <span class="page"> Paper 26540. 16 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Language: English | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1038/s41598-024-77285-x" target="_blank" href="https://doi.org/10.1038/s41598-024-77285-x"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001349432200015" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001349432200015"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85208470617" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85208470617"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="39489756" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39489756&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Journal subject: Scopus - Multidisciplinary&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q1</div> <div class="journal-subject">Committee on Sociology HASSELIX SZTB [1901-]&nbsp;&nbsp;&nbsp;A nemzetközi</div> <div class="journal-subject">Committee on Regional Studies HASSELIX RTB [1901-]&nbsp;&nbsp;&nbsp;B nemzetközi</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="" class="citingPub-count">Citing papers: 4</span> | Independent citation: 2 | Self citation: 2 | Unknown citation: 0 | Number of citations in WoS: 4 | Number of citations in Scopus:&nbsp;2 | WoS/Scopus assigned:&nbsp;4 | Number of citations with DOI:&nbsp;4 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35579438&sort=publishedYear,desc&sort=title"> Number of cited publications: 9 </a> </div> <div class="mtid"><span class="long-pub-mtid">Publication: 35579438</span> | <span class="status-data status-VALIDATED"> Validated </span> Core Citing | <span class="type-subtype">Journal Article ( Article ) </span> | <span class="pub-category">Scientific</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (K135540) Funder: HSRF, (TKP21-EGA25), (NN 114460) Funder: HSRF </div> <div class="lastModified">Last Modified: 2024.11.26. 09:27 Ágnes Szalóky-Siki (SE_KK_Admin5_SZSA, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Comments</u>: These authors contributed equally: Laura Vízkeleti and Orsolya Papp.</pre> </div></div>